Drug intelligence / Profile preview

AGS-006

Development stage: Phase 1
Lead developer: SCM Lifescience
Modality: Vaccines & Immunotherapeutics, Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intradermal, Subcutaneous, Intravenous

Overview

AGS-006 is an autologous therapeutic vaccine developed as an immunotherapy for cancer, specifically studied in a single-patient clinical trial for newly diagnosed resectable pancreatic cancer. It is designed to stimulate the patient's immune system to recognize and attack tumor cells. The therapy involves creating a personalized vaccine using the patient’s own cells, aiming to provide an additional treatment option alongside conventional therapies for pancreatic carcinoma. The developer of AGS-006 is Argos Therapeutics.

Targets

TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on AGS-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGS-006.

Explore the full profile